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Abstract
The use of multiple medications is becoming more common, with a correspondingly increased risk of untoward
effects and drug-related morbidity and mortality. We aimed at estimating the prevalence of prescription of relevant
potentially interacting drugs and at evaluating possible predictors of potentially interacting drug exposure. We
retrospectively analyzed data on prescriptions dispensed from January 2004 to August 2005 to individuals of two
Italian regions with a population of almost 2.1 million individuals. We identified 27 pairs of potentially interacting drugs
by examining clinical relevance, documentation, and volume of use in Italy. Subjects who received at least one
prescription of both drugs were selected. Co-prescribing denotes “two prescriptions in the same day”, and
concomitant medication “the prescription of two drugs with overlapping coverage”. A logistic regression analysis was
conducted to examine the predictors of potential Drug-Drug Interaction (pDDIs). 957,553 subjects (45.3% of study
population) were exposed to at least one of the drugs/classes of the 27 pairs. Overall, pDDIs occurred 2,465,819
times. The highest rates of concomitant prescription and of co-prescription were for ACE inhibitors+NSAIDs (6,253
and 4,621/100,000 plan participants). Considering concomitance, the male/female ratio was <1 in 17/27 pairs (from
0.31 for NSAIDs-ASA+SSRI to 0.74 for omeprazole+clopidogrel). The mean age was lowest for methotrexate pairs
(+omeprazole, 59.9 years; +NSAIDs-ASA, 59.1 years) and highest for digoxin+verapamil (75.4 years). In 13/27 pairs,
the mean ages were ≥70 years. On average, subjects involved in pDDIs received ≥10 drugs. The odds of exposure
were more frequently higher for age ≥65 years, males, and those taking a large number of drugs. A substantial
number of clinically important pDDIs were observed, particularly among warfarin users. Awareness of the most
prevalent pDDIs could help practitioners in preventing concomitant use, resulting in a better quality of drug
prescription and potentially avoiding unwanted side effects.
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Introduction
Quality assessment and improvement in health care is a
major issue in many countries. Information on healthcare is in
demand from policy makers, health-care professionals and the
general public. With the majority of doctor-patient encounters in
general practice resulting in a prescription for drug treatment,
the quality of prescriptions is a critical issue as prescribing
drugs has a major influence on patients’ well-being, and
accounts for a substantial part of health care expenditure.
Drugs are often used in combination to achieve a preferred
therapeutic goal or to treat coexisting diseases. Because of the
risk related to concomitant use of drugs, co-medication has
become a general concern and an important concept in term of
prescribing appropriateness. Some combinations may result in
undesired pharmacodynamic or pharmacokinetic interactions,
resulting in undertreatment or harmful effects [1]. The
consequences of drug-drug interactions (DDIs) can range from
no untoward effects at all, to drug-related mortality. Although
DDIs are considered to be preventable, studies up to 11% of
patients experience symptoms associated with DDIs [2], and
DDIs are responsible for up to 2-3% of hospital admissions
[3,4]. DDIs are associated with increased health care use [5,6].
In the United States, the economic burden of medication-
related morbidity and mortality is as high as $177 billion [7].
Although DDIs are one of the most significant problems with
drug prescribing [8], most physicians are not fully aware of all
major and clinically important drug interactions [9,10], or
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underestimate the risk of the co-administration of multiple
drugs [11]. Furthermore, the pharmacist rarely intervenes when
it recognizes the presence of a potentially clinically important
DDI [12,13]. Research using prescription databases can
contribute to a better understanding of potential DDIs (pDDIs);
however, only a few studies have examined clinically important
DDIs in an outpatient setting, and even fewer have identified
patients at risk [14,15].
The aim of this study was to estimate the prevalence of
some contraindicated/major/moderate pDDIs in the population
registered under the Regional Health Authority of Marche and
Basilicata (central and southern Italy, respectively) during the
period 2004-2005, and to evaluate the association of pDDI with
available patients' characteristics, as age, gender and number
of prescribed drugs.
Methods
This observational, cross-sectional study was part of the
ASSET (Age and Sex Standardised Estimates of Treatment)
project [16], a pharmacoeconomic and
pharmacoepidemiological study. This analysis focused on data
from the Regional Health Departments of Basilicata (a southern
Italian region with almost 600,000 inhabitants) and Marche (a
central Italian region with almost 1.5 million inhabitants), with a
population of slightly more than two million subjects (ASSET
population), 1738 general practitioners (GPs) and 244 family
paediatricians (FPs).
In Italy, retrospective studies using administrative
prescription databases do not require Ethics Committee (EC)
protocol approval or notification [17] therefore we did not
request approval from the EC, nor consult with the EC to
receive a formal written waiver .
Data sources
The Basilicata and Marche Regional Health Departments
collect prescription data from all Local Health Units of the
regions on a monthly basis. These data are grouped in a
regional database that can be linked to other administrative
databases (e.g. with patients’ personal data) using a unique
specific identification code. These prescriptions refer only to
drugs covered by the Italian National Health Service that are
prescribed by GPs and FPs and dispensed by community
pharmacies. The regional prescription database includes a full
account of product dispensed, dates of prescription and
dispensation by community pharmacies, and the personal
identification codes for each patient who receives a
prescription. All prescriptions were classified according to the
Anatomical Therapeutic Chemical (ATC) classification system,
as recommended by the WHO [18], and were identified by their
AIC (authorisation for marketing) number, which allowed us to
determine the specific details and calculate the duration of
each prescription (number of units and dosage). The
demographic data for patients (sex and date of birth) were
available from a regularly updated ad hoc regional database,
which could be linked through patient identification keys.
All personal data (name and identification number) were
replaced by a univocal numerical code, making both databases
anonymous at source in strict compliance with the Italian
Privacy Law (Decree 196, 30/06/2003). The study design
(observational and retrospective in nature) meant that informed
consent was not required from the subjects (Decree 196/03,
art. 110).
Choice of drug pairs
Potential DDIs were identified using the Micromedex®
interaction database. In this system, all drug interactions are
classified according to two parameters. Clinical relevance is
the first, and takes into account potential clinical outcomes, and
the type, quality, and relevance of supporting clinical data. The
classifications for clinical relevance are: Contraindicated (the
drugs are contraindicated for concurrent use), Major (the
interaction may be life-threatening and/or require medical
intervention to minimise or prevent serious adverse effects),
Moderate (the interaction may result in exacerbation of the
patient's condition and/or require an alteration in therapy),
Minor (the interaction would have limited clinical effects;
manifestations may include an increase in the frequency or
severity of the side effects but generally would not require a
major alteration in therapy), and Unknown. The second
parameter is pharmacological documentation: the
classifications in this case are Excellent (controlled studies
have clearly established the existence of the interaction), Good
(documentation strongly suggests the interaction exists, but
well-controlled studies are lacking), Fair (available
documentation is poor, but pharmacological considerations
lead clinicians to suspect the interaction exists, or the
documentation is good for a pharmacologically similar drug)
and Unknown.
The choice of drug pairs was made according to the
following criteria:
• Contraindicated/Major/Moderate for clinical relevance
and/or Excellent/Good for documentation;
• High position in the rankings of use in Italy, on the basis of
OSMED 2004 (an annual national report on drug utilization
and expenditures) [19] for at least one component of the
pair.
The components in the pairs could be a drug class or a
single molecule.
A total of 27 pairs were identified (Table 1 and Table S1),
involving 144 drugs overall (17 single drugs and 8 drug
classes).
Potential DDI assessment
To assess the frequency and distribution of pDDIs, all drug
prescriptions registered from 1 January 2004 to 31 August
2005 were considered (Figure 1). For each drug pair, people
who received at least one prescription were selected to
evaluate the presence of pDDIs and risk factors. We used
defined daily doses (DDDs) from the ATC/DDD system [18] to
construct a proxy measure for a day’s supply. We assumed a
day’s supply for a particular prescription to be equal to the total
amount of drug in the prescription divided by the DDD.
Several patterns of co-medication can be defined [20]. We
investigated two patterns:
Drug-Drug Interactions
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1 Co-prescribing is defined as “the joint prescription of more
than one drug by the physician on the same day”.
2 Concomitant medication is defined as "the prescription of
two drugs with coverage partially overlapping in time, according
to information from the pharmaceutical database".
Co-medication may also result from two drugs being
available to the patient because they have been dispensed
within a certain time period, and some pills are left over. This
latter source of co-medication is strictly dependent on the
patient's behaviour, while co-prescribing and concomitant
medications denote co-medication resulting from the use of
drugs as intended by medical doctors.
Statistical analysis
The unit of analysis was the individual subject. We
enumerated individuals exposed to each of the 27 pDDI
combinations, counting each individual only once for each
combination, irrespective of the number of times he/she was
exposed over the 20-month period.
Case-exposure rates to the pDDIs were calculated as the
number of people exposed to a pDDI divided by the number of
individuals receiving one element of the pair. Rates of
exposure to the pDDIs were calculated for each drug pair, and
were expressed as the number of subjects with a pDDI per
100,000 plan participants (PP, i.e., the enrolled population).
A multivariate logistic regression analysis in each drug cohort
to determine the factors associated with pDDIs was performed.
Exposure to a pDDI (Yes/No) was the dependent variable in
the model. Patient characteristics incorporated in the model as
independent variables included age (<50 [reference]; 50-64;
65-74; ≥75 years), gender (male [reference]; female), and the
number of medications prescribed (<5 [reference]; 5-9; ≥10).
95% confidence intervals around each odds estimate were
calculated.
Table 1. List of the 27 pairs.
1 Simvastatin-Itraconazole 15 Simvastatin-Clarithromycin
2 Metformin-Fluoroquinolones 16 Betablockers-Verapamil
3 Omeprazole-Clopidogrel 17 Simvastatin-Verapamil
4 Warfarin-Amiodarone 18 Enalapril-Allopurinol
5 Warfarin-Moxifloxacin 19 Warfarin-(nsaids or asa)
6 Simvastatin-Amiodarone 20 Methotrexate-(nsaids or asa)
7 Warfarin-Simvastatin 21 Enalapril-asa
8 Digoxin-Verapamil 22 Enalapril-Metformin
9 Warfarin-ssris 23 Warfarin-Itraconazole
10 Verapamil-Atenolol 24 Warfarin-Levothyroxine
11 Heparines-(Nimesulide, Indomethacin, orASA) 25 Simvastatin-Digoxin
12 Amiodarone-Antiarrythmics Ia 26 ace inhibitors-(nsaids or asa)
13 Methotrexate-Omeprazole 27 Ssris-(nsaids or asa)
14 Simvastatin-Gemfibrozil   
SSRIs: selective serotonin reuptake inhibitors, NSAIDs: nonsteroidal
antiinflammatory drugs, ASA: acetylsalicylic acid, ACE: angiotensin converting
enzyme
doi: 10.1371/journal.pone.0078827.t001
All analyses were performed using SPSS® version 16.0.2
(SPSS Inc., IBM Company Headquarters, Chicago, Illinois,
USA).
Results
General prevalence
The study population included 2,115,326 participants (3.6%
of all Italians, population A) (Figure 1).
957,553 subjects (population B) (45.3% of the ASSET
population) were exposed to at least one of the drugs/classes
of the 27 pairs. Of this subpopulation, 18.7% had at least one
overlapping prescription (concomitant patients, population C),
and 13.2% received prescriptions of interacting drugs on the
same day (patients with co-prescription, population D).
Overall, we counted a mean±SD of 13.8±21.0 concomitant
events per patient, and 5.0±5.9 co-prescriptions per patient. In
addition, 25% of patients received at least one concomitant
pDDI in more than one pair, up to a maximum of 9 pairs.
Considering co-prescriptions, the corresponding percentage
decreased to 20%, up to 7 pairs.
Distribution by sex, age and number of prescriptions
Table 2 (and Table S2) shows the main characteristics of the
populations exposed to the 27 pairs of pDDIs.
Considering concomitant prescriptions, the male/female ratio
was <1 in 17/27 pairs of drugs, with the smallest value for the
SSRIs + (NSAIDs or ASA) pair (0.45) and the highest value for
the omeprazole + clopidogrel pair (2.85). For co-prescription,
the male/female ratio was <1 in 16/27 pairs of drugs, with the
smallest and highest values observed for the same pairs as for
concomitant prescriptions (0.43 and 3.06, respectively).
In the cohorts of concomitant prescription-exposed patients,
the lowest mean ages (59.1±15.7; 60.0±15.4) were observed
for methotrexate in both of its pairs (+ omeprazole; + [NSAIDs
or ASA]). The mean age of the patients was ≥75 years for only
one pair (digoxin + verapamil). In 13/27 cases the mean ages
were ≥70 years. The same considerations could be made for
patients with co-prescriptions.
In both cohorts (of patients with concomitant or co-
prescriptions), the mean number of prescribed drugs was ≥10.
Patterns of co-medication
The rates of concomitant prescription (Table S3) were
greatest for persons prescribed with ACE inhibitors + NSAIDs
(6,253.4/100,000 PP), SSRIs + (NSAIDs or ASA)
(1,589.7/100,000 PP), heparines + (nimesulide, indomethacin,
or acetylsalicylic acid) (910.0/100,000 PP), enalapril + ASA
(662.0/100,000 PP) and metformin + fluoroquinolones
(428.6/100,000 PP). The same five pairs showed the highest
rates of co-prescription events, with the same ranking. The
ratio between the subjects with co-prescriptions and the
subjects with concomitant prescriptions was 0.81 (the highest)
for the digoxin + verapamil pair, and 0.24 (the lowest) for the
warfarin + moxifloxacin pair. The most common pDDI was
warfarin + NSAIDs (12,492 subjects; 7,581 with concomitant
prescription and 2804 with co-prescriptions).
Drug-Drug Interactions
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Logistic regression analysis
Table 3 (and Table S4) shows the main results of the logistic
regression analysis. With regard to concomitant events, male
gender conferred an increased risk of pDDIs in 7 pairs for both
cohorts of patients, and in 12 pairs for one of the two involved
cohorts. The highest adjusted odds ratio (aOR) was present in
the omeprazole + clopidogrel pair for patients in the
omeprazole cohort (aOR 3.25, 95% CI 2.82-3.74). In 4 pairs -
verapamil + atenolol, betablockers + verapamil, methotrexate +
(NSAIDs or ASA), and SSRIs + (NSAIDs or ASA)— male
gender decreased the probability of pDDIs. The lowest value
was observed in the warfarin + levothyroxine pair for the
warfarin cohort (aOR 0.41, 95% CI 0.36-0.46). In most cases,
the aOR values for both males and females were quite close to
1.
Generally, ages ≥50 years were associated with an
increased risk; a clear trend was observed in 19 cohorts, with
the strongest evidence in the levothyroxine cohort for warfarin
concomitance (aORs 2.75 [95% CI 2.10-3.61], 6.99 [95% CI
5.38-9.07], and 11.26 [95% CI 8.66-14.63] in the three age
groups, respectively, vs the <50 years class). On the other
hand, in one cohort the aOR decreased with increasing age;
this was the NSAIDs or ASA cohort for methotrexate
concomitance (aORs 0.86 [95% CI 0.76-0.98], 0.74 [95% CI
0.56-0.73], and 0.33 [95% CI 0.28-0.39] in the three age
groups, respectively).
The number of drugs prescribed to the patient during the
study period represented a very strong risk factor for pDDIs.
Omeprazole + clopidogrel was the pair with most pronounced
evidence (omeprazole cohort: aOR 14.12 [95% CI 5.21-38.33]
for 5-9 drugs; aOR 74.00 [95% CI 27.61-198.34] for ≥10 drugs,
vs <5 drugs; clopidogrel cohort: aOR 8.25 [95% CI 2.98-22.87];
aOR 21.65 [95% CI 7.91-59.28] for 5-9 and ≥10 drugs,
respectively). Only in the simvastatin + gemfibrozil pair all
aORs were not significant, also if >1.
For all analysed risk factors, the aORs for coprescription
showed similar patterns, although with milder associations and
not always reaching statistical significance (Table 3 and Table
S4).
Figure 1.  Number and proportion of patients involved in pDDIs.  
doi: 10.1371/journal.pone.0078827.g001
Drug-Drug Interactions
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e78827
Discussion
Only limited recent data are available on the prevalence of
potential DDIs in Italy. The aim of this study was to estimate
the prevalence of clinically relevant pDDIs in general practice
among the approximately 2 million residents of the Basilicata
and Marche regions, and to examine possible predictors of
potential DDI exposure.
These analyses suggested that many patients have been
exposed to the 27 drug combinations identified as clinically
significant, well-documented and widely used in Italy; 8.5% of
the study population received concomitant prescriptions and
6.0% received co-prescriptions of pDDIs.
Considering persons with at least one potential DDI during
the 20-month period, the prevalence estimates applied to the
Italian population resulted in 5.02 million people with pDDIs
(referred only to the 27 pairs), with females accounting for 2.89
million of these, and persons 65 years of age or older for
67.6%. The occurrence of pDDI events in Italy would be 69,259
million, with a ratio of 1 to 3 of co-prescription vs concomitant
events.
Few other studies have evaluated pDDIs in general practice.
A retrospective follow-up study of outpatient prescription data
in Italy found that among more than 4 million subjects, 8,894
clinically important potential DDIs were identified, representing
a 1-year period prevalence of 211 per 100,000 individuals [21].
A register analysis study in general practice carried out in
Denmark found that 6% of the population were exposed to
Table 2. Main characteristics of the populations, N (%).
 
POPULATION A
(ASSET) POPULATION BPOPULATION CPOPULATION D
 N = 2,115,326 N = 957,553 N = 178,796 N = 126,451
GENDER
Male 1,032,357 436,999 78,897 54,932
 (48.8) (45.6) (43.0) (43.4)
Female 1,082,969 520,554 101,917 71,519
 (51.2) (54.4) (57.0) (56.6)
M/F 0.95 0.84 0.75 0.77
AGE CLASSES, years
<50 1,283,070 406,656 16,019 9,758
 (60.7) (42.5) (9.0) (7.7)
50-64 375,404 225,370 41,856 28,299
 (17.8) (23.5) (23.4) (22.4)
65-74 236,764 168,198 56,210 40,440
 (11.2) (17.6) (31.4) (32.0)
>=75 220,088 157,329 64,711 47,954
 (10.4) (16.4) (36.2) (37.9)
PRESCRIBED DRUGS, n
<5 -- 406,549 13,898 9,297
  (42.5) (7.8) (7.4)
5-9 -- 350,488 66,723 46,210
  (36.6) (37.3) (36.5)
>=10 -- 200,516 98,175 70,944
  (20.9) (54.90) (56.1)
doi: 10.1371/journal.pone.0078827.t002
Table 3. Adjusted odds ratios (95% CI) of concomitant
prescription or co-prescription for gender, age, and number
of prescribed drugs.
 Concomitant prescription Co-prescription
 aOR min aOR max aOR min aOR max
 (95% CI) (95% CI) (95% CI) (95% CI)
Female ref ref ref ref
Male 0.41 3.25 0.38 3.46
 (0.36 - 0.46) (2.82 - 3.74) (0.32 -0.44) (2.86 -4.17)
 
for
levothyroxine
concomitance in
warfarin cohort
for clopidogrel
concomitance in
omeprazole
cohort
for
levothyroxine
coprescription
in warfarin
cohort
for clopidogrel
coprescription
in omeprazole
cohort
<50
years ref ref ref ref
50-64
years 0.86 8.44 0.86 9.76
 (0.76 - 0.98) (7.03 - 10.12) (0.75 -0.99) (7.18 -13.27)
 
for metotrexate
concomitance in
NSAIDs-ASA
cohort
for simvastatin
concomitance in
clarithromycin
cohort
for metotrexate
coprescription
in NSAIDs-ASA
cohort
for simvastatin
coprescription
in clarithromycin
cohort
65-74
years 0.26 11.19 0.18 10.86
 (0.13 - 0.49) (9.31 - 13.45) (0.06 -0.51) (7.94 -14.87)
 
for itraconazole
concomitance in
warfarin cohort
for simvastatin
concomitance in
clarithromycin
cohort
for itraconazole
coprescription
in warfarin
cohort
for simvastatin
coprescription
in clarithromycin
cohort
≥75
years 0.20 11.26 0.15 14.89
 (0.11 - 0.38) (8.66 - 14.63) (0.05 -0.42) (10.43 -21.26)
 
for itraconazole
concomitance in
warfarin cohort
for simvastatin
concomitance in
levothyroxine
cohort
for itraconazole
coprescription
in warfarin
cohort
for warfarin
coprescription
in levothyroxine
cohort
<5
drugs ref ref ref ref
5-9
drugs 2.14 14.12 1.92 9.62
 (1.56 - 2.95) (5.21 - 38.33) (1.29 -2.87) (3.51 -26.37)
 
for SSRIs
concomitance in
warfarin cohort
for clopidogrel
concomitance in
omeprazole
cohort
for SSRIs
coprescription
in warfarin
cohort
for clopidogrel
coprescription
in omeprazole
cohort
≥10
drugs 3.21 74.00 3.21 47.54
 (2.97 - 3.48) (27.61 - 198.34) (2.97 -3.48) (17.67 -127.88)
 
for enalapril
concomitance in
ASA cohort
for clopidogrel
concomitance in
omeprazole
cohort
for ASA
coprescription
in enalapril
cohort
for clopidogrel
coprescription
in omeprazole
cohort
aOR: adjusted odds ratio
doi: 10.1371/journal.pone.0078827.t003
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potential drug interactions during a 1-year period [22]. In a
retrospective analysis of the clinical records from 16 general
practitioners in an Italian region, 119 unique severe potential
DDIs occurred 1,037 times in 758 patients (4.7% of the total
number of patients) [23]. Previous studies showed that 0.5–
4.0% of patients are exposed to serious potential drug
interactions in primary health care [1,24,25]. Differences in the
selection of DDIs could explain the differences in the estimated
rates. Many lists of potentially interacting drugs are available
[26–29], and while there is general agreement on their
documentation and clinical relevance, their clinical and
economic burden at the population level strongly depends on
the drugs in the market at a national level and on prescribing
patterns in each local context; this means that comparisons
among different settings are most likely irrelevant.
Nevertheless, the evidence from this and other similar
studies, as well as those derived from hospitals [30,31] and
emergency departments [32,33], show that the pDDIs are a
major issue.
In recent years, an enormous quantity of data on drug
interactions has been published. Although it is likely that pDDIs
are common, only a few of these induce serious adverse
events and often only in predisposed patients [5,33]. Indeed, in
considering the incidence of DDIs, we should distinguish
between potential interactions and interactions that actually
result in clinically adverse effects. In one study [34] of 2,422
patients studied over a period of two months, 113 (4.7%) were
taking drugs that could potentially interact, but only seven
cases showed any clinical evidence of interaction (0.3% of all
the patients; 6.2% of those potentially affected). In a French
study [35] overlooking contraindication to the concomitant drug
use was the most frequent feature in the cases of non-respect
of the Summary of Product Characteristics (38%), but it was
rarely the cause of an adverse drug reaction (6%). Other
studies have also shown that fewer than 11% of the potential
interactions identified for a prescription resulted in an adverse
reaction, and these were rarely the reason for hospital
admission [36,37]. In a review on hospitalisations and
emergency department visits due to drug–drug interactions
[38], DDIs were responsible for 0.05% of the Emergency
Department visits, 0.57% of the admissions and 0.12% of the
re-hospitalisations. We should note that these percentages
may be an underestimation, because it is possible that medical
practitioners and pharmacists did not recognise adverse patient
outcomes caused by DDIs [39,40].
Although the percentages are modest, the number of
adverse outcomes due to DDIs is substantial, because of the
large numbers of ED visits and (re-)hospitalisations. Moreover,
with certain combinations of drugs, there can be consequences
that are very rare but are clinically relevant, or less harmful
consequences that arise more frequently. In both cases, the
overall burden increases with the number of drug users. For
example, in our analysis, NSAIDs—a widely used therapeutic
class [41] involved in seven of the selected pairs—showed the
highest case-exposure rate in combination with ACE inhibitors
(6,253.4/100,000 PP). NSAIDs interact with different groups of
antihypertensive drugs [42,43], reducing their antihypertensive
activity. Although the changes in blood pressure resulting from
this interaction are typically small, some patients can
experience substantial elevations in both systolic and diastolic
blood pressure. A USA study estimated that avoiding minor
changes in systolic pressure in patients with osteoarthritis on
treatment with NSAIDs would have prevented over 30,000
deaths due to stroke, and over 2000 deaths due to coronary
disease [44].
Antibiotics are widely used in Italy, especially those
belonging to the class of fluoroquinolones [41]. Blood glucose
alterations may occur with fluoroquinolones at a higher
incidence than was initially believed [45]. This could be a
significant problem for high-risk patients such as diabetics. In
our analysis, patients exposed to concomitant prescriptions of
metformin and a fluoroquinolone were 428.6/100,000 PP,
implying the need for close monitoring of blood glucose in
these subjects.
Seven of the selected potential DDI types involved warfarin.
Given the narrow International Normalised Ratio (INR) range in
which patients should be maintained, even slight increases or
decreases in drug concentration in the plasma could have
clinically relevant effects. On the other hand, for the same
reasons, patients treated with warfarin are strictly monitored,
and drug doses are adjusted in accordance with changes in the
INR. Since we have no information about the actual
administered doses, it is possible that the high prevalence of
potential DDIs involving warfarin in our observations has not a
high clinical burden.
The only selected pair of drugs with contraindicated
concomitant use, simvastatin + itraconazole, showed a very
low prevalence in the population (15.8/100,000 PP). The use of
itraconazole is not common in primary care, and it is usually
administered under specialist care, meaning that few patients
are exposed to potentially adverse events resulting from these
drug combinations.
Whether two interacting drugs can be used at the same time
without serious consequences depends on whether the benefit
of both drug therapies outweighs the risk of the DDI, taking into
account the availability of alternatives. Our survey assessed
separately concomitant prescription and co-prescription. This
second case—i.e., the prescription of two potentially interacting
drugs on the same day—addresses actual prescriber intention.
The intentional act of co-prescribing may reflect a conscious
choice, driven by the absence of therapeutic alternatives or
accompanied by clear instructions and recommendations to the
patient, but it may also indicate a lack of knowledge and
preparation on the part of the physician. A survey of
prescribers with the Southern California Veterans Affairs
Healthcare System found that clinicians correctly identified only
44% of DDIs [9]. Studies aimed at evaluating pharmacists’
knowledge have also found a low recall of DDIs [46,47]. One
factor that may complicate health professionals’ ability to detect
DDIs is that the number of possible interactions increases as
the number of medications a patient is taking increases [48];
prescribers should recognise that patients often come to them
medicated with several drugs, often acquired from multiple
sources (e.g., over-the-counter and from other prescribers).
Anyhow, physicians cannot be expected to know all of the huge
number of pharmaceuticals available and their potential for
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drug interactions. Computerised drug prescribing alerts could
help them, but are often overridden because of poor specificity
and overload [49,50]. If pharmacists are careful to check the
dispensed drugs and have a good relationship with the
prescriber, they may help to counteract this issue, protecting
patient safety and increasing physician's awareness.
In our analyses, the case-exposure rates of co-prescriptions
were greatest for ACE inhibitors + NSAIDs or ASA
(4,620.6/100,000 PP), SSRIs + NSAIDs or ASA (884.6/100,000
PP), and enalapril + ASA (517.4/100,000 PP). These data
illustrate the extent of the problem of interaction faced by
physicians in managing chronic therapies.
We also assessed the extent of the association between
some factors and the risk of having a pDDI in the pairs included
in the study. In the regression analyses performed for the two
cohorts of exposed patients for each drug pairs (overall 54
analyses), the male gender was a risk factor in 25 analyses
(with a maximum aOR of 3.25 in the omeprazole cohort for
concomitant clopidogrel), an age of ≥75 years was a risk factor
in 36 analyses (with a maximum aOR of 11.26 in the
levothyroxine cohort for concomitant warfarin), and having 10
or more other prescribed drugs was a risk factor in 50 analyses
(with a maximum aOR of 74.00 in the omeprazole cohort for
concomitant clopidogrel). Consistent with these results,
Cruciol-Souza et al. [51] found that the odds of exposure to
potential DDIs were significantly higher in patients aged ≥55
years (OR 1.41) and in those who had been administered more
than 7 drugs (OR 9.91). They found, however, that odds of
exposure were higher among females (OR 1.23). This
difference could depend on list of pDDIs choice, or from
differences in prescribing habits. In the study by Bjerrum et al.,
patient-related factors associated with the increased risk of
potential drug interactions were a high age and a high number
of concurrently used drugs [22]. Gagne et al. found that the
odds of exposure were highest among those aged 65 years or
older, males, and those with more chronic conditions. The odds
of exposure increased by 1.39 times with each addition of a
prescription medication [21]. As expected, older age and
polytherapy, two conditions that are closely related, greatly
increase the risk of interaction; these factors may be used by
physicians to identify fragile patients who should receive
maximum attention to the potential for DDIs.
The major limitation of our study is that we did not assess the
harm associated with potentially hazardous interactions, and
therefore the exposure rates may overestimate the real clinical
impact of DDIs. It was also not possible to determine whether
the choice of drugs was deliberate, and whether it was
preceded by a careful evaluation of the risk-benefit ratio
(including available treatment options and therapeutic goals)
and was accompanied by proper instructions to the patient, to
minimise the risk of adverse events. Furthermore, our study
was limited by the number and type of interactions evaluated,
and by the dataset. First, different results may have been
obtained, to the extent that other interactions were selected.
Second, similar to many other databases, ASSET depends on
the Italian reimbursement system. Consequently, we may not
have recognised other potentially serious interactions, and we
could have underestimated the actual magnitude of some
selected pDDIs (e.g., those involving NSAIDs), since only
NHS-covered prescribed medications were included and not
OTC non-prescription medications, or herbal and/or home
remedies. Drugs dispensed in hospitals and nursing homes
were also not included in the study. In addition, the estimated
time of prescription coverage based on the DDDs actually
provides only a rough evaluation of the timing of use. Finally,
we do not know whether the prescribed medicines were taken.
This limitation, however, is less relevant if we look at the results
from the point of view of the appropriateness of the prescription
habits of physicians.
Conclusions
Limited to the 27 selected drugs pairs, we observed that
males, elderly and people taking multiple medications were
more frequently exposed to a concomitant or co-prescription of
potentially interacting drugs. These results can guide the
interventions by health authorities, aimed at containing the
epidemiological impact of the pDDIs. On the other hand, the
different rates of exposure in the two genders or in the age
classes do not involve less attention by the physician in respect
of those subjects that showed a lower probability of being
exposed to pDDIs. Most importantly, clinicians should
recognise that each medication added to a therapeutic regimen
significantly increase the risk of patients' exposure to potential
DDIs.
The noticeably high number of subjects exposed to pDDIs —
with many of them experiencing multiple episodes during the
observation period, and many taking more than one pair of
interacting drugs— should encourage health authorities to
develop new effective strategies, since the computerised tools
available to support the prescription process are not generally
used by physicians. We suggest, for example, that an
institutional Committee of experts outline a list of DDIs based
both on the clinical relevance of the interaction and on the
prevalence of drug use, thus defining an indicator of
appropriate prescribing; this should be evaluated by all regions
to have a complete national picture on which educational
prescriber-targeted strategies can be drawn.
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